How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,313 results for

Six Item Cognitive Impairment Test

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems

of nicotine dependence related to cigarette smoking. It contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. Timeline Followback Method Assessment [ Time Frame: Once a week for 8 weeks ] The Timeline Followback (TLFB) is a method that can be used as a clinical and research tool to obtain a variety of quantitative estimates of marijuana, cigarette, and other drug use. Contemplation Ladder [ Time Frame: Once a week for 8 weeks ] A measure (...) Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2015 Clinical Trials

142. Feasibility Testing and Evaluation of an Online Toolkit for Male Spouses of Women With Breast Cancer

] Caregiver quality of life is measured by the Caregiver Quality of Life-Cancer (CQOL-C) scale. This scale was developed specifically for family caregivers of persons with cancer. It consists of 35 items using a five-point Likert-type scale. It has four sub-scales: burden (physical and emotional), disruptiveness, positive adaptation and financial concerns. Higher scores reflect higher quality of life. It can be completed in 10 minutes and is considered easy to use. Test-retest reliability was found (...) and older (Adult, Older Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: male 18 years of age or older living with a spouse who has breast cancer (Stage 1, 2, or 3) English speaking. Exclusion Criteria: persons who are non-autonomous adults cognitively impaired as determined by the Registered Nurse (RN) researcher unable to participate, in the opinion of the RN researcher non-English speaking does not have a spouse who is diagnosed with having breast

2014 Clinical Trials

143. Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. (PubMed)

. The patients were divided into 3 groups (no cognitive impairment [NCI], mild cognitive impairment [MCI], dementia) and rated for cognitive performance with the MMSE before first ECT, after sixth ECT, and 6 weeks and 6 months after ECT termination. Affective symptoms were rated by 21-item Hamilton Depression Rating Scale (HDRS-21) before and 6 weeks after ECT. Analysis of variance or Kruskal-Wallis tests on ECT-induced MMSE and HDRS-21 score changes were compared to baseline. Binary logistic regression (...) Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. To study cognitive performance in depressed geriatric inpatients with or without preexisting cognitive impairment who received a first course of electroconvulsive therapy (ECT).Forty-four elderly inpatients with major depressive disorder (ICD-10 criteria) were included in a prospective consecutive case series of a university hospital

2010 Journal of Clinical Psychiatry

144. Depressive symptoms predict incident cognitive impairment in cognitive healthy older women. (PubMed)

Medicine.Community-based sample of 436 older, nondemented women.Participants were followed up with regular medical and neuropsychiatric evaluations. Cognitive assessment included episodic immediate and delayed memory, psychomotor speed, and executive functioning. Participants were characterized as having incident impairment on a cognitive test when scores fell below the 10th percentile on age-adjusted norms. Baseline depressive symptoms were measured using the Geriatric Depression Scale (GDS) (30-item). Discrete (...) Depressive symptoms predict incident cognitive impairment in cognitive healthy older women. There is an increasing evidence that depressive symptoms are associated with the development of cognitive impairment and dementia in late life. The authors sought to examine whether depression increased the risk of incident cognitive impairment in a longitudinal study of older women.Observational study, up to six examinations spanning up to 9 years.University-based Division of Geriatric

Full Text available with Trip Pro

2010 The American Journal of Geriatric Psychiatry

145. Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia. (PubMed)

of social skills.These analyses suggest that the six MCCB "domains" as constructed can be collapsed into fewer domains composed of multiple item scores; they also support the notion that impaired processing speed is a fundamental cognitive deficit in schizophrenia and that MCCB performance is related to functional capacity. Cognition and functional capacity measures require more research to determine if they differ.Published by Elsevier B.V. (...) and determine whether its cognitive domains are separable.183 outpatients with schizophrenia or schizoaffective disorder completed a comprehensive test battery. Confirmatory factor analysis was used to test the factor structure of the MCCB; hierarchical regression then examined the relative contribution of individual cognitive variables to predict the MCCB factor scores. Finally, the relationships between the resulting factors and two performance-based measures of functional capacity were explored.A three

Full Text available with Trip Pro

2013 Schizophrenia Research

146. A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

Test Part A; Brief Assessment in Cognition in Schizophrenia Symbol Coding; Hopkins Verbal Learning Test-Revised; Wechsler Memory Scale-III Spatial Span; Letter Number Sequencing; Neuropsychological Assessment Battery Mazes; Brief Visuospatial Memory Test-Revised; Category Fluency Animal Naming; Mayer-Salovey-Caruso Emotional Intelligence Test Managing Emotions; and Continuous Performance Test-Identical Pairs. For each test, a score is derived based on the raw item values. Each of the individual (...) : placebo capsules Outcome Measures Go to Primary Outcome Measures : Visual Memory [ Time Frame: Baseline, 8 weeks, and 16 weeks ] To determine the efficacy of adjunctive valacyclovir, in comparison to placebo, to improve visual memory (Brief Visuospatial Memory Test) in individuals who are HSV-1 positive and early in the course of schizophrenia. The Brief Visuospatial Memory Test is a subscale of the MATRICS Consensus Cognitive Battery (MCCB) and was used to assess visual memory. The BVMT consists

2013 Clinical Trials

147. Cognitive Rehabilitation Versus Psychoeducation in Psychosocial Functioning of Borderline Personality Disorder

is a 24-item scale that measures the level of psychosocial functioning of patients in daily life situations. It assesses six functional domains: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time. Higher scores indicate higher functional impairment. This instrument has shown good psychometric properties and sensitivity to change. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate (...) Cognitive Rehabilitation Versus Psychoeducation in Psychosocial Functioning of Borderline Personality Disorder Cognitive Rehabilitation Versus Psychoeducation in Psychosocial Functioning of Borderline Personality Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2013 Clinical Trials

148. Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study

Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02033161 Recruitment Status : Completed First

2013 Clinical Trials

149. Estrogen Receptors Beta (ER-B) as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X (TESXF)

of phosphatidylinositol 3-kinase (PI3K)and mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK1/2). This study targets the synaptic plasticity alterations that underlie the learning and memory impairment but also the computational disability in FXS. The hypothesis is that EGCG can act by favoring the physiological processes involved in cognition. Condition or disease Intervention/treatment Phase Fragile X Syndrome Dietary Supplement: EGCG Dietary Supplement: Placebo Other: cognitive (...) of a list of 12 items, which have to be verbally recalled by the examinee during 3 trials of free and cued recall. The test start with a learning phase where the examinee is required to learn the list of 12 items using 12 images. Four pictures are presented at a time, one in each quadrant of a card. First, the examinee have to name each of the four pictures in the card, and secondly assign each picture according to a verbal category-cue given by the examiner. Changes in language (Boston Naming Test

2013 Clinical Trials

150. Combination Treatment Study for Memory Impairment and Depression

six trials (total immediate recall) was obtained. Selective Reminding Test (SRT) Delayed Recall [ Time Frame: Week 16 ] The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) and delayed recall (after a 15-minute delay) was obtained. Secondary Outcome Measures : Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) [ Time Frame: Week 16 ] The modified ADAS-Cog is a cognitive (...) : Of either sex, age 55-95 years old with minimum 8 years of education who meet criteria for both depression and cognitive impairment as described below. Study Criteria for "depression": i. Patients who meet DSM-IV symptom criteria for Major Depression or Dysthymia for a minimum of 6 months (2 year duration DSM-IV TR criterion not required for dysthymic disorder in this study). ii. 24-item HAM-D ≥14. Study Criteria for "cognitive impairment": i. Subjective memory or other cognitive complaints. ii. Score

2012 Clinical Trials

151. Testing the Efficacy of Self-Generation Treatment Protocol

treatment self-generation strategy treatment, embedded within practice of various activities Behavioral: Self-generation treatment self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks Placebo Comparator: memory training Treatment consists on traditional memory training Outcome Measures Go (...) Testing the Efficacy of Self-Generation Treatment Protocol Testing the Efficacy of Self-Generation Treatment Protocol - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Testing the Efficacy of Self-Generation

2013 Clinical Trials

152. Combining Exercise and Cognitive Training to Improve Everyday Function

contraindications to exercise or evidence of dementia or cognitive impairment. Individuals will be randomly assigned to one of four groups for six months: Aerobic Exercise and Health Education, Home Exercise and Cognitive Training, Aerobic Exercise and Cognitive Training, and Home Exercise and Health Education. Participants will undergo measurements of cognitive function, physical performance, and complete questionaires about daily activities, physical activity, and quality of life at baseline (pre-intervention (...) weekly metabolic work (KCals). Uniform Data Set (UDS) [ Time Frame: Baseline, Month 12 ] A standardized interview to ascertain and assess demographic information, health status, cognitive status, medications, and functional status. The interview is conducted with the research participant and a collateral source historian. Geriatric Depression Scale [ Time Frame: Baseline, Month 12 ] A 15-item questionnaire to assess for symptoms of depression. Late Life Function & Disability Index (LLFDI) [ Time

2012 Clinical Trials

153. Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

are also taking stable antipsychotic therapy. Condition or disease Intervention/treatment Phase Schizophrenia Impaired Cognition Drug: EVP-6124 Drug: Placebo Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 753 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized (...) General health status acceptable for participation in a 26-week clinical study Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study Fluency (oral and written) in the language in which the standardized tests will be administered The ability to refrain from using any tobacco or other nicotine-containing products for at least 30 minutes before any cognitive testing Exclusion Criteria: Hospitalization within 12 weeks before screening or during

2012 Clinical Trials

154. Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

are also taking stable antipsychotic therapy. Condition or disease Intervention/treatment Phase Schizophrenia Impaired Cognition Drug: EVP-6124 Drug: Placebo Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 767 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized (...) General health status acceptable for participation in a 26-week clinical study Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study Fluency (oral and written) in the language in which the standardized tests will be administered The ability to refrain from using any tobacco or other nicotine-containing products for at least 30 minutes before any cognitive testing Exclusion Criteria: Hospitalization within 12 weeks before screening or during

2012 Clinical Trials

155. Compensatory Strategies Applied to Cognitive Impairment in Schizophrenia

Description: It is estimated that approximately 80% of patients with schizophrenia have reduced cognitive functions, representing problems with attention, verbal memory, short-term memory and executive functions (1-3). These impairments might have an impact on the patients ability to complete rehabilitation programmes, apply learned strategies to social problems, develop work skills and manage daily life (4,5). The effect of Cognitive Adaptation Training has been tested as a psychosocial treatment (...) Adaptation No Intervention: Treatment as ususal Pharmacological treatment, weekly contact to professionals (often in patient's homes), psychoeducation, social skill training in groups and psychosocial intervention with relatives. Outcome Measures Go to Primary Outcome Measures : Changes in Social functioning assessed by Global Assessment of Function test and Health of the Nation Outcome Scales item 9-12 concerning social problems. [ Time Frame: Baseline, six month and nine month. ] The effect

2010 Clinical Trials

156. Hemoglobin Concentration and Cognitive Impairment in the Renal REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. (PubMed)

in Stroke study. Cognitive impairment was defined as a score of 4 or less on the six-item screener. Hemoglobin was analyzed in 1 g/dL increments relative to the World Health Organization (WHO) threshold (<13 g/dL for men and <12 g/dL for women).The mean hemoglobin concentration was 13.7 ± 1.5 g/dL. The prevalence of cognitive impairment increased from 4.3% among individuals with a hemoglobin >3 g/dL above the WHO threshold to 16.8% for those with a hemoglobin ≥2 g/dL below the WHO threshold. After (...) adjustment for demographics, chronic health conditions, health status, and inflammation, the association between reduced hemoglobin and cognitive impairment was attenuated and no longer significant, including among those with hemoglobin ≥2 g/dL below the WHO threshold (odds ratio 1.39, 95% confidence interval = 0.94-2.04). A test for linear trend was of borderline significance (p value = .06). For 94% of the sample within 2 g/dL of the WHO threshold, there was no relationship between hemoglobin

Full Text available with Trip Pro

2010 Biological Sciences and Medical Sciences

157. The Effect of Rasagiline on Cognition in Parkinson's Disease

: Placebo Participants in this group will receive 1 mg of placebo daily for the six month duration of the study. Drug: Placebo 1 mg daily Outcome Measures Go to Primary Outcome Measures : Rey Auditory Verbal Learning Test [ Time Frame: Change in score from day 1 of study enrollment and score after 6 months of treatment ] This is a 15 item supraspan verbal memory test. This measure assesses immediate memory span, new learning, susceptibility to interference, retention, and recognition memory. Secondary (...) . Frakey, Brown University Study Details Study Description Go to Brief Summary: While Parkinson's disease has historically been defined in terms of its motor symptomatology, studies have shown that non-motor deficits form an important part of the syndrome. Cognitive deficits can occur even in the early stages of Parkinson's disease. These deficits are often subtle and do not rise to the level of impairment necessary for a diagnosis of dementia; however these deficits are discernable

2011 Clinical Trials

158. 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

impairment). Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale [ Time Frame: Days 1 (baseline) and 91 ] Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. A summary measure of executive function was constructed by converting raw scores from 9 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort (...) in brain glucose utilization, using FDG-PET voxel-based analysis. Estimate the effect size of MSDC-0160 treatment versus placebo on 3-month change in cognitive function as determined by global cognitive function on a neuropsychological battery of 19 tests. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in cognitive function as determined by the ADAS-Cog subscale. Estimate the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. Explore

2011 Clinical Trials

159. D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)

compulsive disorder. This study represents an innovative approach in translating bench research findings into clinical research and testing a new approach for optimizing an effective psychotherapy with a safe non-psychotropic medication. Condition or disease Intervention/treatment Phase Obsessive-compulsive Disorder Behavioral: Cognitive-behavioral therapy Drug: d-cycloserine Drug: Pill placebo Phase 3 Detailed Description: Obsessive-compulsive disorder (OCD) affects 1-2% of children, runs a chronic (...) course without treatment, and is associated with considerable functional impairment and poor quality of life. Although most patients with OCD respond to cognitive-behavioral therapy (CBT) or pharmacotherapy with a serotonin reuptake inhibitor (SRI), a substantial number of youth remain symptomatic after receiving these therapies. Pharmacological interventions with SRIs are only moderately efficacious, rarely produce remission, may be accompanied by side effects, and may not be an acceptable

2011 Clinical Trials

160. Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

scan performed in the last six months. Patients with cognitive impairment at screening, defined as at least one test of the Rao's Brief Repeatable Battery with scores falling outside the 90th percentile of the normative data. Exclusion Criteria: Patients who had already been treated with multiweekly interferon (interferon beta 1b, or beta 1a multiweekly) and had an unsatisfactory response according to the judgment of the investigator. Patients with hyperactive forms of the MS disease according (...) ): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: The purpose of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduction of cognitive dysfunction progression in RRMS patients after 18 months of treatment with fingolimod in comparison with interferon beta 1b treatment, and to evaluate which test of the battery is the most sensitive

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>